Status:

UNKNOWN

Detection of Tumor DNA in Blood Samples From Cancer Patients

Lead Sponsor:

Lexent Bio, Inc.

Conditions:

Cancer

Tumors

Eligibility:

All Genders

18+ years

Brief Summary

The aim of this study is to employ genomic detection methodologies to measure the relative amount of tumor nucleic acids in the blood of a cancer patient with diagnosed metastatic disease that is eith...

Eligibility Criteria

Inclusion

  • Age 18 years or older
  • Have metastatic disease with from a solid tumor (e.g. breast, lung, colon, pancreas, ovary, prostate...) or stage II or III solid tumors undergoing curative surgery or neoadjuvant therapy followed by surgery
  • Starting treatment or a new line of treatment
  • Able to understand and grant informed consent
  • Able to have their blood drawn

Exclusion

  • Unable to grant informed consent or comply with all study procedures.
  • Has a hematological malignancy, i.e. myeloma, lymphoma, MDS, leukemia

Key Trial Info

Start Date :

December 1 2014

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

November 1 2020

Estimated Enrollment :

500 Patients enrolled

Trial Details

Trial ID

NCT02288754

Start Date

December 1 2014

End Date

November 1 2020

Last Update

August 14 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cancer Care Associates

Torrance, California, United States, 90277

Detection of Tumor DNA in Blood Samples From Cancer Patients | DecenTrialz